Danaher (Danaher) Debt-to-Asset : 0.22 (As of Mar. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Danaher Debt-to-Asset?

Danaher's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1,746 Mil. Danaher's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16,417 Mil. Danaher's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $83,402 Mil. Danaher's debt to asset for the quarter that ended in Mar. 2024 was 0.22.

Danaher Debt-to-Asset Historical Data

The historical data trend for Danaher's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Debt-to-Asset Chart

Danaher Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.36

0.29

0.28

0.24

0.23

Danaher Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.23	0.23	0.25	0.23	0.22

Competitive Comparison of Danaher's Debt-to-Asset

For the Diagnostics & Research subindustry, Danaher's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danaher's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Danaher's Debt-to-Asset falls into.

Danaher Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Danaher's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1875	+	17661)	/	84488
	=	0.23

Danaher's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1746	+	16417)	/	83402
	=	0.22

Danaher (NYSE:DHR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Danaher Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Danaher's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Danaher (Danaher) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DHR:Mexico 1DHR:Italy DAPd:UK DAP:Germany DAP:Germany DAP:Germany DHER34:Brazil DHRC:Austria

Address

2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701

Website

https://www.danaher.com

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.

Executives

Jose-carlos Gutierrez-ramos	officer: SVP, Chief Scientific Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Linda Filler	director	2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Daniel Raskas	officer: VP-Corporate Development	2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Teri List	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr	director	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Georgeann Couchara	officer: SVP, Human Resources	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew	officer: EVP & Chief Financial Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Jennifer Honeycutt	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Alan G Spoon	director	1150 15TH ST NW, WASHINGTON DC 20071
Rainer Blair	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan	director	C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales	director, officer: Chairman of Exec. Committee	11790 GLEN ROAD, POTOMAC MD 20854
Brian W Ellis	officer: Senior Vice President - GC	2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037